In vitro synergy of fusidic acid and amikacin against methicillin resistant Staphlococus aureus

Pakistan Journal of Medical Sciences

Volumn 23, Issue 2, 2007, Pages 245-248

  Perwaiz, Samia ^a,b   Barakzai, Qamaruddin ^a   Farooqi, Badar Jehan ^a   Sabir, Nasim ^a  

^a ZIAUDDIN MEDICAL UNIVERSITY   (Pakistan)

^b NONE   (Pakistan)

Author keywords

Amikacin; Fusidic acid; MRSA; Synergism; Vancomycin

Indexed keywords

AMIKACIN; CEFALEXIN; CLINDAMYCIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; OFLOXACIN; OXACILLIN; TEICOPLANIN; VANCOMYCIN;

ANALYTIC METHOD; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DILUTION; DRUG POTENTIATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 34249745310     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Michel M, Gutmann L. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: Therapeutic realities possibilities. Lancet 1997;349:1901-6.
2. Center of Disease Control. Laboratory detection of oxacillin / methicillin-resistant Staphylococcus aureus. 2, 2005.
3. Smith TL, Pearson ML, Wilcox KL, Cruz C, Lancaster MV. Emergence of Vancomycin resistance in Staphylococcus aureus. N Eng J Med 1999;340: 493-501.
4. Sieradzki K , Roberts RB, Haber S, Tomasz A. The development of vancomycin resistance in a patient with methicillin -resistant Staphylococuus aureus infection. N Eng J Med 1999;340:517-53.
5. Bukhari MH, Iqbal A, Khatoon N, Iqbal N, Naeem S, Qureshi GR , et al. A laboratory study of susceptibility of methicillin resistant Staphylococcus aureus. Pak J Med Sci 2004;20:229-33.
6. Andrews JM. Determination of minimum inhibitory concentration. J Antimicrob Chemother 2001;48,S1,5-16.
7. NCCLS. Approved standard M7-A4: methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed. Villanova, Pennsylvannia 1997.
8. McClatchey KD. Antimicrobial Susceptibility Testing. In: Clinical laboratory medicine, William & Wilkins, 1994.
9. Climo MW, Patron RL, Archer GL. Combination of vancomycin and â-lactams are synergistic against Staphylococci with reduced susceptibility to vancomycin. J. Antimicrob. Chemother 1999;43:1747-53.
10. Levy SB. The Challenge of Antibiotic Resistance. Scientific American, 1998;32-9.
11. Fey PD, Said-Salim B, Rupp ME, Hinrichs SH, Boxrud DJ, Davis CC, et al. Comparative molecular analysis of community or hospital-acquired methicillin-resistant staphylococcus aureus. J Antimicrob Chemother 2003;47:196-203.
12. Domaracki BE, Evans AM, Venezia RA. Vancomycin and oxacillin synergy for methicillin-resistant staphylococci. J Antimicrob Chemother 2000;1394-96.
13. Rochon-Edouard S, Pestel-Caron M, Lemeland JF, and Caron F. In Vitro Synergistic Effects of Double and Triple Combinations of â-Lactams, Vancomycin, and Netilmicin against Methicillin-Resistant Staphylococcus aureus Strains. J Antimicob Agent Chemother 2000;44:3055-60.
14. Totsuka K, Shiseki M, Kikuchi K. and Matsul Y. Combined effects of vancomycin and imipenem against MRSA in vitro and in vivo. J Antimicrob Chemother 1999;455-60.
15. Drancourt M. Oral treatment of staphylococcus spp. Infected orthopedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997;39:235-40.
16. O'Neill AJ. Antimicobial activity and mechanisms of resistance to Cephalosporin P1, an antibiotic related to fusidic acid. J Antimicrob Chemother 2002;50:839-48.
17. Collignon P, Turnidge J. Fusidic acid in vitro activity. International Journal of Antimicrobial Agents 1999;S45-58.
18. Drugeon HB, Caillon J, Juvin ME. In-vitro antibacterial activity of fusidic acid alone and in combination with other antibiotics against methicillin-sensitive and resistant Staphylococcus aureus. J Antimicrob Chemother 1994;34:899.
19. Whitby M. Fusidic acid in the treatment of methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 1999;S67-71.